Amalgamated Bank Purchases Shares of 30,239 Revvity, Inc. (NYSE:RVTY)

Amalgamated Bank acquired a new position in shares of Revvity, Inc. (NYSE:RVTY) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 30,239 shares of the company’s stock, valued at approximately $3,305,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. acquired a new position in Revvity during the 3rd quarter valued at $1,579,487,000. Ceredex Value Advisors LLC acquired a new position in shares of Revvity in the fourth quarter valued at $108,353,000. Swiss National Bank bought a new stake in Revvity in the 4th quarter valued at $42,434,000. Sumitomo Mitsui Trust Holdings Inc. bought a new position in shares of Revvity during the 4th quarter worth about $33,568,000. Finally, Boston Trust Walden Corp acquired a new stake in shares of Revvity during the 4th quarter valued at about $25,154,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Stock Performance

RVTY stock opened at $104.34 on Friday. The company has a 50 day moving average price of $104.29 and a 200 day moving average price of $101.30. Revvity, Inc. has a fifty-two week low of $79.50 and a fifty-two week high of $131.96. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.23 and a quick ratio of 1.92. The stock has a market capitalization of $12.89 billion, a PE ratio of 86.23, a price-to-earnings-growth ratio of 2.62 and a beta of 1.09.

Revvity (NYSE:RVTY) last released its earnings results on Monday, April 29th. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. The company had revenue of $649.90 million during the quarter, compared to the consensus estimate of $646.83 million. Revvity had a return on equity of 7.37% and a net margin of 5.49%. The firm’s quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.01 earnings per share. Analysts forecast that Revvity, Inc. will post 4.66 EPS for the current year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be paid a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date of this dividend is Friday, July 19th. Revvity’s dividend payout ratio (DPR) is 23.14%.

Analysts Set New Price Targets

Several research firms recently issued reports on RVTY. Robert W. Baird increased their price target on shares of Revvity from $126.00 to $127.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 30th. KeyCorp raised their target price on Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. Raymond James upped their price target on Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. TD Cowen lifted their price objective on Revvity from $123.00 to $130.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Finally, Barclays upped their target price on shares of Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Revvity currently has a consensus rating of “Moderate Buy” and an average target price of $118.17.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.